Efficacy of Re-treatment With Cimzia® in Subject With Chronic Plaque Psoriasis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00329303|
Recruitment Status : Completed
First Posted : May 24, 2006
Last Update Posted : September 9, 2013
|Condition or disease||Intervention/treatment||Phase|
|Psoriasis||Drug: Certolizumab pegol (cimzia®)||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||75 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Efficacy and Safety of Re-treatment With Cimzia® at 2 Dose Regimens for 12 Weeks in Subject Suffering From Moderate to Severe Chronic Plaque Psoriasis Having Relapsed After Response to First Treatment|
|Study Start Date :||April 2006|
|Actual Primary Completion Date :||May 2007|
|Actual Study Completion Date :||May 2007|
- To assess the efficacy of re-treatment with cimzia® compared to first treatment in patients having relapsed after response to first treatment.
- To describe safety of re-treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00329303
|Nice Cedex 3, France|
|Pierre Benite, France|
|Study Director:||UCB Clinical Trial Call Center||UCB Pharma|